{
    "id": "dbpedia_8538_2",
    "rank": 89,
    "data": {
        "url": "https://www.nature.com/articles/s41575-024-00962-9",
        "read_more_link": "",
        "language": "en",
        "title": "Cellular and molecular basis of proximal small intestine disorders",
        "top_image": "https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41575-024-00962-9/MediaObjects/41575_2024_962_Fig1_HTML.png",
        "meta_img": "https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41575-024-00962-9/MediaObjects/41575_2024_962_Fig1_HTML.png",
        "images": [
            "https://pubads.g.doubleclick.net/gampad/ad?iu=/285/naturereviews.gastrohep/article&sz=728x90&c=1911063064&t=pos%3Dtop%26type%3Darticle%26artid%3Ds41575-024-00962-9%26doi%3D10.1038/s41575-024-00962-9%26subjmeta%3D1503,4017,4020,692%26kwrd%3DGastrointestinal+diseases,Molecular+medicine",
            "https://media.springernature.com/full/nature-cms/uploads/product/nrgastro/header-d20dff524a6b100a963ae009056760e6.svg",
            "https://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fs41575-024-00962-9/MediaObjects/41575_2024_962_Fig1_HTML.png",
            "https://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fs41575-024-00962-9/MediaObjects/41575_2024_962_Fig2_HTML.png",
            "https://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fs41575-024-00962-9/MediaObjects/41575_2024_962_Fig3_HTML.png",
            "https://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fs41575-024-00962-9/MediaObjects/41575_2024_962_Fig4_HTML.png",
            "https://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fs41575-024-00962-9/MediaObjects/41575_2024_962_Fig5_HTML.png",
            "https://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fs41575-024-00962-9/MediaObjects/41575_2024_962_Fig6_HTML.png",
            "https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs41385-021-00398-3/MediaObjects/41385_2021_398_Fig1_HTML.png",
            "https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs12276-024-01179-1/MediaObjects/12276_2024_1179_Fig1_HTML.png",
            "https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs41575-020-0331-7/MediaObjects/41575_2020_331_Fig1_HTML.png",
            "https://pubads.g.doubleclick.net/gampad/ad?iu=/285/naturereviews.gastrohep/article&sz=300x250&c=-1273697291&t=pos%3Dright%26type%3Darticle%26artid%3Ds41575-024-00962-9%26doi%3D10.1038/s41575-024-00962-9%26subjmeta%3D1503,4017,4020,692%26kwrd%3DGastrointestinal+diseases,Molecular+medicine",
            "https://www.nature.com/static/images/logos/sn-logo-white-ea63208b81.svg",
            "https://www.nature.com/static/images/logos/nature-briefing-logo-n150-white-d81c9da3ec.svg",
            "https://verify.nature.com/verify/nature.png",
            "https://www.nature.com/x9wavqvr/preview/s41575-024-00962-9"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [
            "Charbit-Henrion",
            "Cerf-Bensussan",
            "Holm H"
        ],
        "publish_date": "2024-08-08T00:00:00",
        "summary": "",
        "meta_description": "The proximal part of the small intestine, including duodenum and jejunum, is not only dedicated to nutrient digestion and absorption but is also a highly regulated immune site exposed to environmental factors. Host-protective responses against pathogens and tolerance to food antigens are essential functions in the small intestine. The cellular ecology and molecular pathways to maintain those functions are complex. Maladaptation is highlighted by common immune-mediated diseases such as coeliac disease, environmental enteric dysfunction or duodenal Crohn’s disease. An expanding spectrum of more than 100 rare monogenic disorders inform on causative molecular mechanisms of nutrient absorption, epithelial homeostasis and barrier function, as well as inflammatory immune responses and immune regulation. Here, after summarizing the architectural and cellular traits that underlie the functions of the proximal intestine, we discuss how the integration of tissue immunopathology and molecular mechanisms can contribute&nbsp;towards&nbsp;our understanding of disease and guide diagnosis. We propose an integrated mechanism-based taxonomy and discuss the latest experimental approaches to gain new mechanistic insight into these disorders with large disease burden worldwide as well as implications for therapeutic interventions. The proximal small intestine is key for nutrition, metabolism and immune responses, and can be affected by a wide range of disorders. This Review describes the cellular and molecular bases of diseases of the proximal small intestine (including rare monogenic disorders), proposing a mechanism-based taxonomy.",
        "meta_lang": "en",
        "meta_favicon": "/static/images/favicons/nature/apple-touch-icon-f39cb19454.png",
        "meta_site_name": "Nature",
        "canonical_link": "https://www.nature.com/articles/s41575-024-00962-9",
        "text": "Volk, N. & Lacy, B. Anatomy and physiology of the small bowel. Gastrointest. Endosc. Clin. N. Am. 27, 1–13 (2017).\n\nEarley, Z. M. et al. GATA4 controls regionalization of tissue immunity and commensal-driven immunopathology. Immunity 56, 43–57.e10 (2023).\n\nSpencer, N. J. & Hu, H. Enteric nervous system: sensory transduction, neural circuits and gastrointestinal motility. Nat. Rev. Gastroenterol. Hepatol. 17, 338–351 (2020).\n\nMcCarthy, N., Kraiczy, J. & Shivdasani, R. A. Cellular and molecular architecture of the intestinal stem cell niche. Nat. Cell Biol. 22, 1033–1041 (2020).\n\nHeel, K. A., McCauley, R. D., Papadimitriou, J. M. & Hall, J. C. Review: Peyer’s patches. J. Gastroenterol. Hepatol. 12, 122–136 (1997).\n\nMcCarthy, N. et al. Distinct mesenchymal cell populations generate the essential intestinal BMP signaling gradient. Cell Stem Cell 26, 391–402.e395 (2020).\n\nHickey, J. W. et al. Organization of the human intestine at single-cell resolution. Nature 619, 572–584 (2023).\n\nBeumer, J. et al. BMP gradient along the intestinal villus axis controls zonated enterocyte and goblet cell states. Cell Rep. 38, 110438 (2022).\n\nMcConnell, R. E., Benesh, A. E., Mao, S., Tabb, D. L. & Tyska, M. J. Proteomic analysis of the enterocyte brush border. Am. J. Physiol. Gastrointest. Liver Physiol. 300, G914–G926 (2011).\n\nBusslinger, G. A. et al. Human gastrointestinal epithelia of the esophagus, stomach, and duodenum resolved at single-cell resolution. Cell Rep. 34, 108819 (2021).\n\nWallaeys, C., Garcia-Gonzalez, N. & Libert, C. Paneth cells as the cornerstones of intestinal and organismal health: a primer. EMBO Mol. Med. 15, e16427 (2023).\n\nLueschow, S. R. & McElroy, S. J. The Paneth cell: the curator and defender of the immature small intestine. Front. Immunol. 11, 587 (2020).\n\nBany Bakar, R., Reimann, F. & Gribble, F. M. The intestine as an endocrine organ and the role of gut hormones in metabolic regulation. Nat. Rev. Gastroenterol. Hepatol. 20, 784–796 (2023).\n\nBeumer, J. et al. High-resolution mRNA and secretome atlas of human enteroendocrine cells. Cell 181, 1291–1306.e1219 (2020).\n\nGerbe, F. et al. Distinct ATOH1 and Neurog3 requirements define tuft cells as a new secretory cell type in the intestinal epithelium. J. Cell Biol. 192, 767–780 (2011).\n\nGerbe, F. et al. Intestinal epithelial tuft cells initiate type 2 mucosal immunity to helminth parasites. Nature 529, 226–230 (2016).\n\nHendel, S. K. et al. Tuft cells and their role in intestinal diseases. Front. Immunol. 13, 822867 (2022).\n\nMabbott, N. A., Donaldson, D. S., Ohno, H., Williams, I. R. & Mahajan, A. Microfold (M) cells: important immunosurveillance posts in the intestinal epithelium. Mucosal Immunol. 6, 666–677 (2013).\n\nPowell, D. W., Pinchuk, I. V., Saada, J. I., Chen, X. & Mifflin, R. C. Mesenchymal cells of the intestinal lamina propria. Annu. Rev. Physiol. 73, 213–237 (2011).\n\nSmillie, C. S. et al. Intra- and inter-cellular rewiring of the human colon during ulcerative colitis. Cell 178, 714–730.e722 (2019).\n\nHolloway, E. M. et al. Mapping development of the human intestinal niche at single-cell resolution. Cell Stem Cell 28, 568–580.e564 (2021).\n\nRamirez, M., Pell, N., Mejias, M. & Fernandez, M. Pericyte biology in different organs. Adv. Exp. Med. Biol. 1122, 73–100 (2019).\n\nCarloni, S. & Rescigno, M. Unveiling the gut-brain axis: structural and functional analogies between the gut and the choroid plexus vascular and immune barriers. Semin. Immunopathol. 44, 869–882 (2022).\n\nCifarelli, V. & Eichmann, A. The intestinal lymphatic system: functions and metabolic implications. Cell Mol. Gastroenterol. Hepatol. 7, 503–513 (2019).\n\nZarkada, G. et al. Chylomicrons regulate lacteal permeability and intestinal lipid absorption. Circ. Res. 133, 333–349 (2023).\n\nFriedrich, M. et al. IL-1-driven stromal–neutrophil interactions define a subset of patients with inflammatory bowel disease that does not respond to therapies. Nat. Med. 27, 1970–1981 (2021).\n\nCadinu, P. et al. Charting the cellular biogeography in colitis reveals fibroblast trajectories and coordinated spatial remodeling. Cell 187, 2010–2028 e2030 (2024).\n\nThomsen, L. et al. Interstitial cells of Cajal generate a rhythmic pacemaker current. Nat. Med. 4, 848–851 (1998).\n\nCardoso, V. et al. Neuronal regulation of type 2 innate lymphoid cells via neuromedin U. Nature 549, 277–281 (2017).\n\nMatheis, F. et al. Adrenergic signaling in muscularis macrophages limits infection-induced neuronal loss. Cell 180, 64–78.e16 (2020).\n\nMuller, P. A. et al. Crosstalk between muscularis macrophages and enteric neurons regulates gastrointestinal motility. Cell 158, 300–313 (2014).\n\nViola, M. F. et al. Dedicated macrophages organize and maintain the enteric nervous system. Nature 618, 818–826 (2023).\n\nYang, D. et al. Nociceptor neurons direct goblet cells via a CGRP-RAMP1 axis to drive mucus production and gut barrier protection. Cell 185, 4190–4205.e4125 (2022).\n\nYe, L. et al. Enteroendocrine cells sense bacterial tryptophan catabolites to activate enteric and vagal neuronal pathways. Cell Host Microbe 29, 179–196.e179 (2021).\n\nMowat, A. M. To respond or not to respond - a personal perspective of intestinal tolerance. Nat. Rev. Immunol. 18, 405–415 (2018).\n\nBujko, A. et al. Transcriptional and functional profiling defines human small intestinal macrophage subsetsMacrophage subsets in human small intestine. J. Exp. Med. 215, 441–458 (2018).\n\nStagg, A. J. Intestinal dendritic cells in health and gut inflammation. Front. Immunol. 9, 2883 (2018).\n\nBrandtzaeg, P. Mucosal immunity: induction, dissemination, and effector functions. Scand. J. Immunol. 70, 505–515 (2009).\n\nSpencer, J. & Bemark, M. Human intestinal B cells in inflammatory diseases. Nat. Rev. Gastroenterol. Hepatol. 20, 254–265 (2023).\n\nFadlallah, J. et al. Microbial ecology perturbation in human IgA deficiency. Sci. Transl. Med. 10, eaan1217 (2018).\n\nMayassi, T. & Jabri, B. Human intraepithelial lymphocytes. Mucosal Immunol. 11, 1281–1289 (2018).\n\nBartolome-Casado, R. et al. Resident memory CD8 T cells persist for years in human small intestine. J. Exp. Med. 216, 2412–2426 (2019).\n\nGray, J. I. & Farber, D. L. Tissue-resident immune cells in humans. Annu. Rev. Immunol. 40, 195–220 (2022).\n\nEttersperger, J. et al. Interleukin-15-dependent T-cell-like innate intraepithelial lymphocytes develop in the intestine and transform into lymphomas in celiac disease. Immunity 45, 610–625 (2016).\n\nLevescot, A., Malamut, G. & Cerf-Bensussan, N. Immunopathogenesis and environmental triggers in coeliac disease. Gut 71, 2337–2349 (2022).\n\nBanyai, K., Estes, M. K., Martella, V. & Parashar, U. D. Viral gastroenteritis. Lancet 392, 175–186 (2018).\n\nRossi, C. et al. Histopathology of intestinal villi in neonatal and paediatric age: main features with clinical correlation - Part II. Pathologica 114, 22–31 (2022).\n\nKhan, F. et al. Crohn’s-like enteritis in X-linked agammaglobulinemia: a case series and systematic review. J. Allergy Clin. Immunol. Pract. 9, 3466–3478 (2021).\n\nPanarelli, N. C. & Yantiss, R. K. Inflammatory and infectious manifestations of immunodeficiency in the gastrointestinal tract. Mod. Pathol. 31, 844–861 (2018).\n\nUdgirkar, S. et al. Gastroduodenal tuberculosis: a case series and review of literature. Clin. Med. Insights Gastroenterol. 11, 1179552218790566 (2018).\n\nMarth, T. Systematic review: Whipple’s disease (Tropheryma whipplei infection) and its unmasking by tumour necrosis factor inhibitors. Aliment. Pharmacol. Ther. 41, 709–724 (2015).\n\nAl-Saleem, T. & Al-Mondhiry, H. Immunoproliferative small intestinal disease (IPSID): a model for mature B-cell neoplasms. Blood 105, 2274–2280 (2005).\n\nHu, L. M. et al. Clinicopathological analysis of 12 patients with Epstein–Barr virus-positive primary intestinal T/natural killer-cell lymphoma (EBV+ ITNKL). Histopathology 70, 1052–1063 (2017).\n\nKul Cinar, O., Romano, M., Guzel, F., Brogan, P. A. & Demirkaya, E. Paediatric Behcet’s disease: a comprehensive review with an emphasis on monogenic mimics. J. Clin. Med. 11, 1278 (2022).\n\nCrane, R. J., Jones, K. D. & Berkley, J. A. Environmental enteric dysfunction: an overview. Food Nutr. Bull. 36, S76–S87 (2015).\n\nCollard, J. M. et al. High prevalence of small intestine bacteria overgrowth and asymptomatic carriage of enteric pathogens in stunted children in Antananarivo, Madagascar. PLoS Negl. Trop. Dis. 16, e0009849 (2022).\n\nCowardin, C. A. et al. Environmental enteric dysfunction: gut and microbiota adaptation in pregnancy and infancy. Nat. Rev. Gastroenterol. Hepatol. 20, 223–237 (2023).\n\nQuigley, E. M. M., Murray, J. A. & Pimentel, M. AGA clinical practice update on small intestinal bacterial overgrowth: expert review. Gastroenterology 159, 1526–1532 (2020).\n\nBushyhead, D. & Quigley, E. M. M. Small intestinal bacterial overgrowth-pathophysiology and its implications for definition and management. Gastroenterology 163, 593–607 (2022).\n\nAlper, A. et al. Prevalence and clinical, endoscopic, and pathological features of duodenitis in children. J. Pediatr. Gastroenterol. Nutr. 62, 314–316 (2016).\n\nLaube, R. et al. Oral and upper gastrointestinal Crohn’s disease. J. Gastroenterol. Hepatol. 33, 355–364 (2018).\n\nLebwohl, B. & Rubio-Tapia, A. Epidemiology, presentation, and diagnosis of celiac disease. Gastroenterology 160, 63–75 (2021).\n\ndu Pre, M. F., Iversen, R. & Sollid, L. M. Coeliac disease: the paradox of diagnosing a food hypersensitivity disorder with autoantibodies. Gut 73, 844–853 (2024).\n\nTrynka, G. et al. Dense genotyping identifies and localizes multiple common and rare variant association signals in celiac disease. Nat. Genet. 43, 1193–1201 (2011).\n\nBouziat, R. et al. Reovirus infection triggers inflammatory responses to dietary antigens and development of celiac disease. Science 356, 44–50 (2017).\n\nMalamut, G., Soderquist, C. R., Bhagat, G. & Cerf-Bensussan, N. Advances in nonresponsive and refractory celiac disease. Gastroenterology 167, 132–147 (2024).\n\nAbou Rached, A. & El Hajj, W. Eosinophilic gastroenteritis: approach to diagnosis and management. World J. Gastrointest. Pharmacol. Ther. 7, 513–523 (2016).\n\nGiannetti, A. et al. Cow’s milk protein allergy as a model of food allergies. Nutrients 13, 1525 (2021).\n\nCatanzaro, R., Sciuto, M. & Marotta, F. Lactose intolerance: an update on its pathogenesis, diagnosis, and treatment. Nutr. Res. 89, 23–34 (2021).\n\nShulman, H. M. et al. NIH consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. The 2014 Pathology Working Group Report. Biol. Blood Marrow Transpl. 21, 589–603 (2015).\n\nBadran, Y. R. et al. Immune checkpoint inhibitor-associated celiac disease. J. Immunother. Cancer 8, e000958 (2020).\n\nScialom, S. et al. Gastrointestinal disorder associated with olmesartan mimics autoimmune enteropathy. PLoS ONE 10, e0125024 (2015).\n\nScarpignato, C. & Bjarnason, I. Drug-induced small bowel injury: a challenging and often forgotten clinical condition. Curr. Gastroenterol. Rep. 21, 55 (2019).\n\nde Dreuille, B. et al. Unexpected upper gastrointestinal polyps in patients with short bowel syndrome treated with teduglutide: need for close monitoring. Am. J. Clin. Nutr. 117, 1143–1151 (2023).\n\nPevny, S. et al. De novo development of distal jejunal and duodenal adenomas after 41 months of teduglutide treatment in a patient with short-bowel syndrome: a case report. JPEN J. Parenter. Enter. Nutr. 45, 652–656 (2021).\n\nWildin, R. S. et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat. Genet. 27, 18–20 (2001).\n\nDuclaux-Loras, R. et al. Clinical heterogeneity of immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome: a french multicenter retrospective study. Clin. Transl. Gastroenterol. 9, 201 (2018).\n\nGambineri, E. et al. Clinical, immunological, and molecular heterogeneity of 173 patients with the phenotype of immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome. Front. Immunol. 9, 2411 (2018).\n\nZhang, Z. et al. Human interleukin-2 receptor beta mutations associated with defects in immunity and peripheral tolerance. J. Exp. Med. 216, 1311–1327 (2019).\n\nCepika, A. M. et al. Tregopathies: monogenic diseases resulting in regulatory T-cell deficiency. J. Allergy Clin. Immunol. 142, 1679–1695 (2018).\n\nKuehn, H. S. et al. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science 345, 1623–1627 (2014).\n\nLo, B. et al. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy. Science 349, 436–440 (2015).\n\nMitsuiki, N., Schwab, C. & Grimbacher, B. What did we learn from CTLA-4 insufficiency on the human immune system? Immunol. Rev. 287, 33–49 (2019).\n\nSchwab, C. et al. Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects. J. Allergy Clin. Immunol. 142, 1932–1946 (2018).\n\nPhilips, R. L. et al. The JAK-STAT pathway at 30: much learned, much more to do. Cell 185, 3857–3876 (2022).\n\nOkada, S. et al. Human STAT1 gain-of-function heterozygous mutations: chronic mucocutaneous candidiasis and type I interferonopathy. J. Clin. Immunol. 40, 1065–1081 (2020).\n\nLeiding, J. W. et al. Monogenic early-onset lymphoproliferation and autoimmunity: natural history of STAT3 gain-of-function syndrome. J. Allergy Clin. Immunol. 151, 1081–1095 (2023).\n\nRodari, M. M. et al. Insights into the expanding intestinal phenotypic spectrum of SOCS1 haploinsufficiency and therapeutic options. J. Clin. Immunol. 135, 1403–1413 (2023).\n\nParlato, M. et al. Loss-of-function mutation in PTPN2 causes aberrant activation of JAK signaling via STAT and very early onset intestinal inflammation. Gastroenterology 159, 1968–1971.e1964 (2020).\n\nSharma, M. et al. Human germline heterozygous gain-of-function STAT6 variants cause severe allergic disease. J. Exp. Med. 220, e20221755 (2023).\n\nHoresh, M. E. et al. Individuals with JAK1 variants are affected by syndromic features encompassing autoimmunity, atopy, colitis, and dermatitis. J. Exp. Med. 221, e20232387 (2024).\n\nAbolhassani, H., Hammarstrom, L. & Cunningham-Rundles, C. Current genetic landscape in common variable immune deficiency. Blood 135, 656–667 (2020).\n\nMartelius, T., Seppanen, M. R. J. & Warnatz, K. Editorial: updates on the pathogenesis of common variable immunodeficiency (CVID). Front. Immunol. 13, 1130418 (2022).\n\nMalamut, G. et al. The enteropathy associated with common variable immunodeficiency: the delineated frontiers with celiac disease. Am. J. Gastroenterol. 105, 2262–2275 (2010).\n\nvan Schewick, C. M. et al. Bowel histology of CVID patients reveals distinct patterns of mucosal inflammation. J. Clin. Immunol. 42, 46–59 (2022).\n\nCunningham-Rundles, C. Common variable immune deficiency: dissection of the variable. Immunol. Rev. 287, 145–161 (2019).\n\nFourgeaud, J. et al. Chronic aichi virus infection as a cause of long-lasting multiorgan involvement in patients with primary immune deficiencies. Clin. Infect. Dis. 77, 620–628 (2023).\n\nPosovszky, C. et al. Persisting enteropathy and disturbed adaptive mucosal immunity due to MHC class II deficiency. Clin. Immunol. 203, 125–133 (2019).\n\nDhekne, H. S. et al. MYO5B, STX3, and STXBP2 mutations reveal a common disease mechanism that unifies a subset of congenital diarrheal disorders: a mutation update. Hum. Mutat. 39, 333–344 (2018).\n\nBabcock, S. J., Flores-Marin, D. & Thiagarajah, J. R. The genetics of monogenic intestinal epithelial disorders. Hum. Genet. 142, 613–654 (2022).\n\nDuclaux-Loras, R. et al. UNC45A deficiency causes microvillus inclusion disease-like phenotype by impairing myosin VB-dependent apical trafficking. J. Clin. Invest. 132, e154997 (2022).\n\nRossi, C. et al. Histopathology of intestinal villi in neonatal and paediatric age: main features with clinical correlation - Part I. Pathologica 114, 12–21 (2022).\n\nDas, B. & Sivagnanam, M. Congenital tufting enteropathy: biology, pathogenesis and mechanisms. J. Clin. Med. 10, 19 (2020).\n\nHeinz-Erian, P. et al. Mutations in SPINT2 cause a syndromic form of congenital sodium diarrhea. Am. J. Hum. Genet. 84, 188–196 (2009).\n\nFiskerstrand, T. et al. Familial diarrhea syndrome caused by an activating GUCY2C mutation. N. Engl. J. Med. 366, 1586–1595 (2012).\n\nWolfe, R. M. et al. Novel GUCY2C variant causing familial diarrhea in a Mennonite kindred and a potential therapeutic approach. Am. J. Med. Genet. A 185, 2046–2055 (2021).\n\nNorsa, L. et al. Inflammatory bowel disease in patients with congenital chloride diarrhoea. J. Crohns Colitis 15, 1679–1685 (2021).\n\nRao, M. C. Physiology of electrolyte transport in the gut: implications for disease. Compr. Physiol. 9, 947–1023 (2019).\n\nSeidler, U. & Nikolovska, K. Slc26 family of anion transporters in the gastrointestinal tract: expression, function, regulation, and role in disease. Compr. Physiol. 9, 839–872 (2019).\n\nO’Connell, A. E. et al. Neonatal-onset chronic diarrhea caused by homozygous nonsense WNT2B mutations. Am. J. Hum. Genet. 103, 131–137 (2018).\n\nChen, J. et al. Expression and function of the epidermal growth factor receptor in physiology and disease. Physiol. Rev. 96, 1025–1069 (2016).\n\nBandsma, R. H. et al. Loss of ADAM17 is associated with severe multiorgan dysfunction. Hum. Pathol. 46, 923–928 (2015).\n\nBlaydon, D. C. et al. Inflammatory skin and bowel disease linked to ADAM17 deletion. N. Engl. J. Med. 365, 1502–1508 (2011).\n\nAl-Shaibi, A. A. et al. Human AGR2 deficiency causes mucus barrier dysfunction and infantile inflammatory bowel disease. Cell Mol. Gastroenterol. Hepatol. 12, 1809–1830 (2021).\n\nThiagarajah, J. R. et al. Advances in evaluation of chronic diarrhea in infants. Gastroenterology 154, 2045–2059 e2046 (2018).\n\nOz-Levi, D. et al. Noncoding deletions reveal a gene that is critical for intestinal function. Nature 571, 107–111 (2019).\n\nWang, J. et al. Mutant neurogenin-3 in congenital malabsorptive diarrhea. N. Engl. J. Med. 355, 270–280 (2006).\n\nPiccand, J. et al. Rfx6 promotes the differentiation of peptide-secreting enteroendocrine cells while repressing genetic programs controlling serotonin production. Mol. Metab. 29, 24–39 (2019).\n\nBourgeois, P. et al. Tricho-hepato-enteric syndrome mutation update: mutations spectrum of TTC37 and SKIV2L, clinical analysis and future prospects. Hum. Mutat. 39, 774–789 (2018).\n\nAvitzur, Y. et al. Mutations in tetratricopeptide repeat domain 7A result in a severe form of very early onset inflammatory bowel disease. Gastroenterology 146, 1028–1039 (2014).\n\nSalter, C. G. et al. Biallelic PI4KA variants cause neurological, intestinal and immunological disease. Brain 144, 3597–3610 (2021).\n\nBigorgne, A. E. et al. TTC7A mutations disrupt intestinal epithelial apicobasal polarity. J. Clin. Invest. 124, 328–337 (2014).\n\nWoutsas, S. et al. Hypomorphic mutation in TTC7A causes combined immunodeficiency with mild structural intestinal defects. Blood 125, 1674–1676 (2015).\n\nJonassaint, N. L., Guo, N., Califano, J. A., Montgomery, E. A. & Armanios, M. The gastrointestinal manifestations of telomere-mediated disease. Aging Cell 12, 319–323 (2013).\n\nUmeno, J. et al. A hereditary enteropathy caused by mutations in the SLCO2A1 gene, encoding a prostaglandin transporter. PLoS Genet. 11, e1005581 (2015).\n\nHamon, A. et al. Crohn-like disease affecting small bowel due to monogenic SLCO2A1 mutations: first cases of chronic enteropathy associated with SLCO2A1 gene (CEAS) in France. J. Crohns Colitis 17, 816–820 (2022).\n\nAdler, D. H. et al. Inherited human cPLA(2alpha) deficiency is associated with impaired eicosanoid biosynthesis, small intestinal ulceration, and platelet dysfunction. J. Clin. Invest. 118, 2121–2131 (2008).\n\nTsuchida, N. et al. Haploinsufficiency of A20 caused by a novel nonsense variant or entire deletion of TNFAIP3 is clinically distinct from Behcet’s disease. Arthritis Res. Ther. 21, 137 (2019).\n\nShiraki, M., Kadowaki, S., Kadowaki, T., Kawamoto, N. & Ohnishi, H. Primary immunodeficiency disease mimicking pediatric Bechet’s disease. Children 8, 75 (2021).\n\nHuppmann, A. R. et al. Pathologic findings in NEMO deficiency: a surgical and autopsy survey. Pediatr. Dev. Pathol. 18, 387–400 (2015).\n\nMeyer, S. et al. AIRE-deficient patients harbor unique high-affinity disease-ameliorating autoantibodies. Cell 166, 582–595 (2016).\n\nPosovszky, C. et al. Loss of enteroendocrine cells in autoimmune-polyendocrine-candidiasis-ectodermal-dystrophy (APECED) syndrome with gastrointestinal dysfunction. J. Clin. Endocrinol. Metab. 97, E292–E300 (2012).\n\nKluger, N., Jokinen, M., Krohn, K. & Ranki, A. Gastrointestinal manifestations in APECED syndrome. J. Clin. Gastroenterol. 47, 112–120 (2013).\n\nHaque, T. T. et al. TGFbeta prevents IgE-mediated allergic disease by restraining T follicular helper 2 differentiation. Sci. Immunol. 9, eadg8691 (2024).\n\nRodari, M. M., Cerf-Bensussan, N. & Parlato, M. Dysregulation of the immune response in TGF-beta signalopathies. Front. Immunol. 13, 1066375 (2022).\n\nRamos, A. F. et al. Cystic fibrosis, gastroduodenal inflammation, duodenal ulcer, and H. pylori infection: the “cystic fibrosis paradox” revisited. J. Cyst. Fibros. 12, 377–383 (2013).\n\nShah, N. et al. Enteropathic histopathological features may be associated with Shwachman-Diamond syndrome. J. Clin. Pathol. 63, 592–594 (2010).\n\nElkadri, A. et al. Mutations in plasmalemma vesicle associated protein result in sieving protein-losing enteropathy characterized by hypoproteinemia, hypoalbuminemia, and hypertriglyceridemia. Cell Mol. Gastroenterol. Hepatol. 1, 381–394.e387 (2015).\n\nOzen, A. et al. CD55 deficiency, early-onset protein-losing enteropathy, and thrombosis. N. Engl. J. Med. 377, 52–61 (2017).\n\nVignes, S. & Bellanger, J. Primary intestinal lymphangiectasia (Waldmann’s disease). Orphanet J. Rare Dis. 3, 5 (2008).\n\nAlders, M. et al. Mutations in CCBE1 cause generalized lymph vessel dysplasia in humans. Nat. Genet. 41, 1272–1274 (2009).\n\nAlders, M. et al. Hennekam syndrome can be caused by FAT4 mutations and be allelic to Van Maldergem syndrome. Hum. Genet. 133, 1161–1167 (2014).\n\nBrouillard, P. et al. Loss of ADAMTS3 activity causes Hennekam lymphangiectasia-lymphedema syndrome 3. Hum. Mol. Genet. 26, 4095–4104 (2017).\n\nScheuerle, A. E. et al. An additional case of Hennekam lymphangiectasia-lymphedema syndrome caused by loss-of-function mutation in ADAMTS3. Am. J. Med. Genet. A 176, 2858–2861 (2018).\n\nSoblet, J. et al. Blue Rubber Bleb Nevus (BRBN) syndrome is caused by somatic TEK (TIE2) mutations. J. Invest. Dermatol. 137, 207–216 (2017).\n\nSeront, E., Boon, L. M. & Vikkula, M. TEK-related venous malformations. GeneReviews (Univ. Washington) (2023).\n\nOstermaier, K. K. et al. Incidence of celiac disease in down syndrome: a longitudinal, population-based birth cohort study. Clin. Pediatr. 59, 1086–1091 (2020).\n\nFerrari, M. & Stagi, S. Autoimmunity and genetic syndromes: a focus on down syndrome. Genes 12, 268 (2021).\n\nAl-Bluwi, G. S. M., AlNababteh, A. H., Ostlundh, L., Al-Shamsi, S. & Al-Rifai, R. H. Prevalence of celiac disease in patients with turner syndrome: systematic review and meta-analysis. Front. Med. 8, 674896 (2021).\n\nBethell, G. S., Long, A. M., Knight, M., Hall, N. J. & Baps, C. The impact of trisomy 21 on epidemiology, management, and outcomes of congenital duodenal obstruction: a population-based study. Pediatr. Surg. Int. 36, 477–483 (2020).\n\nHeindl, M. et al. Autoimmunity, intestinal lymphoid hyperplasia, and defects in mucosal B-cell homeostasis in patients with PTEN hamartoma tumor syndrome. Gastroenterology 142, 1093–1096.e1096 (2012).\n\nWangler, M. F. et al. Heterozygous de novo and inherited mutations in the smooth muscle actin (ACTG2) gene underlie megacystis-microcolon-intestinal hypoperistalsis syndrome. PLoS Genet. 10, e1004258 (2014).\n\nGamboa, H. E. & Sood, M. Pediatric intestinal pseudo-obstruction in the era of genetic sequencing. Curr. Gastroenterol. Rep. 21, 70 (2019).\n\nChetaille, P. et al. Mutations in SGOL1 cause a novel cohesinopathy affecting heart and gut rhythm. Nat. Genet. 46, 1245–1249 (2014).\n\nPaszkowski, J. et al. Endoscopic surveillance and treatment of upper GI tract lesions in patients with familial adenomatous polyposis-A new perspective on an old disease. Genes 13, 2329 (2022).\n\nGorji, L. & Albrecht, P. Hamartomatous polyps: diagnosis, surveillance, and management. World J. Gastroenterol. 29, 1304–1314 (2023).\n\nTaylor, H. et al. mTOR inhibitors reduce enteropathy, intestinal bleeding and colectomy rate in patients with juvenile polyposis of infancy with PTEN-BMPR1A deletion. Hum. Mol. Genet. 30, 1273–1282 (2021).\n\nGelsomino, F., Balsano, R., De Lorenzo, S. & Garajova, I. Small bowel adenocarcinoma: from molecular insights to clinical management. Curr. Oncol. 29, 1223–1236 (2022).\n\nMarsh, M. N. Gluten, major histocompatibility complex, and the small intestine. A molecular and immunobiologic approach to the spectrum of gluten sensitivity (‘celiac sprue’). Gastroenterology 102, 330–354 (1992).\n\nCanani, R. B., Castaldo, G., Bacchetta, R., Martin, M. G. & Goulet, O. Congenital diarrhoeal disorders: advances in this evolving web of inherited enteropathies. Nat. Rev. Gastroenterol. Hepatol. 12, 293–302 (2015).\n\nTangye, S. G. et al. Human inborn errors of immunity: 2022 update on the classification from the international union of immunological societies expert committee. J. Clin. Immunol. 42, 1473–1507 (2022).\n\nvan Rheenen, P. F. et al. The medical management of paediatric Crohn’s disease: an ECCO-ESPGHAN guideline update. J Crohns Colitis, https://doi.org/10.1093/ecco-jcc/jjaa161 (2020).\n\nHusby, S. et al. European society paediatric gastroenterology, hepatology and nutrition guidelines for diagnosing coeliac disease 2020. J. Pediatr. Gastroenterol. Nutr. 70, 141–156 (2020).\n\nMaaser, C. et al. ECCO-ESGAR guideline for diagnostic assessment in IBD Part 1: initial diagnosis, monitoring of known IBD, detection of complications. J. Crohns Colitis 13, 144–164 (2019).\n\nLichtenstein, G. R. et al. ACG clinical guideline: management of Crohn’s disease in adults. Am. J. Gastroenterol. 113, 481–517 (2018).\n\nAl-Toma, A. et al. European Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gluten-related disorders. Eur. Gastroenterol. J. 7, 583–613 (2019).\n\nUhlig, H. H. et al. Clinical genomics for the diagnosis of monogenic forms of inflammatory bowel disease: a position paper from the Paediatric IBD Porto group of European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J. Pediatr. Gastroenterol. Nutr. 72, 456–473 (2021).\n\nMatthijs, G. et al. Guidelines for diagnostic next-generation sequencing. Eur. J. Hum. Genet. 24, 2–5 (2016).\n\nDanan, C. H., Katada, K., Parham, L. R. & Hamilton, K. E. Spatial transcriptomics add a new dimension to our understanding of the gut. Am. J. Physiol. Gastrointest. Liver Physiol. 324, G91–G98 (2023).\n\nPopovic, D. et al. The importance of artificial intelligence in upper gastrointestinal endoscopy. Diagnostics 13, 2862 (2023).\n\nChetcuti Zammit, S. et al. Towards the probabilistic analysis of small bowel capsule endoscopy features to predict severity of duodenal histology in patients with villous atrophy. J. Med. Syst. 44, 195 (2020).\n\nStoleru, C. A., Dulf, E. H. & Ciobanu, L. Automated detection of celiac disease using machine learning algorithms. Sci. Rep. 12, 4071 (2022).\n\nWei, J. W. et al. Automated detection of celiac disease on duodenal biopsy slides: a deep learning approach. J. Pathol. Inf. 10, 7 (2019).\n\nMolder, A., Balaban, D. V., Jinga, M. & Molder, C. C. Current evidence on computer-aided diagnosis of celiac disease: systematic review. Front. Pharmacol. 11, 341 (2020).\n\nAtlasy, N. et al. Single cell transcriptomic analysis of the immune cell compartment in the human small intestine and in celiac disease. Nat. Commun. 13, 4920 (2022).\n\nLindeman, I. & Sollid, L. M. Single-cell approaches to dissect adaptive immune responses involved in autoimmunity: the case of celiac disease. Mucosal Immunol. 15, 51–63 (2022).\n\nKummerlowe, C. et al. Single-cell profiling of environmental enteropathy reveals signatures of epithelial remodeling and immune activation. Sci. Transl. Med. 14, eabi8633 (2022).\n\nJarosch, S. et al. Multimodal immune cell phenotyping in GI biopsies reveals microbiome-related T cell modulations in human GvHD. Cell Rep. Med. 4, 101125 (2023).\n\nSchneeberger, K. et al. An inducible mouse model for microvillus inclusion disease reveals a role for myosin Vb in apical and basolateral trafficking. Proc. Natl Acad. Sci. USA 112, 12408–12413 (2015).\n\nJardine, S. et al. Drug screen identifies leflunomide for treatment of inflammatory bowel disease caused by TTC7A deficiency. Gastroenterology 158, 1000–1015 (2020).\n\nGoettel, J. A. et al. Fatal autoimmunity in mice reconstituted with human hematopoietic stem cells encoding defective FOXP3. Blood 125, 3886–3895 (2015).\n\nBouffi, C. et al. In vivo development of immune tissue in human intestinal organoids transplanted into humanized mice. Nat. Biotechnol. 41, 824–831 (2023).\n\nAbadie, V., Khosla, C. & Jabri, B. A mouse model of celiac disease. Curr. Protoc. 2, e515 (2022).\n\nDotsenko, V., Sioofy-Khojine, A. B., Hyoty, H. & Viiri, K. Human intestinal organoid models for celiac disease research. Methods Cell Biol. 179, 173–193 (2023).\n\nPoplaski, V. et al. Human intestinal organoids from Cronkhite–Canada syndrome patients reveal link between serotonin and proliferation. J. Clin. Invest. 133, e166884 (2023).\n\nKasendra, M. et al. Duodenum intestine-chip for preclinical drug assessment in a human relevant model. eLife 9, e50135 (2020).\n\nShin, W. & Kim, H. J. 3D in vitro morphogenesis of human intestinal epithelium in a gut-on-a-chip or a hybrid chip with a cell culture insert. Nat. Protoc. 17, 910–939 (2022).\n\nWagar, L. E. et al. Modeling human adaptive immune responses with tonsil organoids. Nat. Med. 27, 125–135 (2021).\n\nAlhassan, E., Yadav, A., Kelly, C. P. & Mukherjee, R. Novel nondietary therapies for celiac disease. Cell Mol. Gastroenterol. Hepatol. 8, 335–345 (2019).\n\nSchuppan, D. et al. A randomized trial of a transglutaminase 2 inhibitor for celiac disease. N. Engl. J. Med. 385, 35–45 (2021).\n\nSollid, L. M. Tolerance-inducing therapies in coeliac disease - mechanisms, progress and future directions. Nat. Rev. Gastroenterol. Hepatol. 21, 335–347 (2024).\n\nKliewer, K. L. et al. One-food versus six-food elimination diet therapy for the treatment of eosinophilic oesophagitis: a multicentre, randomised, open-label trial. Lancet Gastroenterol. Hepatol. 8, 408–421 (2023).\n\nLevine, A. et al. Crohn’s disease exclusion diet plus partial enteral nutrition induces sustained remission in a randomized controlled trial. Gastroenterology 157, 440–450 e448 (2019).\n\nTickell, K. D., Atlas, H. E. & Walson, J. L. Environmental enteric dysfunction: a review of potential mechanisms, consequences and management strategies. BMC Med. 17, 181 (2019).\n\nKocoshis, S. A. et al. Safety and efficacy of teduglutide in pediatric patients with intestinal failure due to short bowel syndrome: a 24-week, phase III study. J. Parenter. Enter. Nutr. 44, 621–631 (2020).\n\nZorzetti, N. et al. Small bowel transplant - novel indications and recent progress. Expert Rev. Gastroenterol. Hepatol. 17, 677–690 (2023).\n\nKim, Y. K. RNA therapy: rich history, various applications and unlimited future prospects. Exp. Mol. Med. 54, 455–465 (2022).\n\nAlmeqdadi, M., Mana, M. D., Roper, J. & Yilmaz, O. H. Gut organoids: mini-tissues in culture to study intestinal physiology and disease. Am. J. Physiol. Cell Physiol. 317, C405–C419 (2019).\n\nTakahashi, T. Organoids for drug discovery and personalized medicine. Annu. Rev. Pharmacol. Toxicol. 59, 447–462 (2019).\n\nDate, A. A., Hanes, J. & Ensign, L. M. Nanoparticles for oral delivery: design, evaluation and state-of-the-art. J. Control. Rel. 240, 504–526 (2016).\n\nMose, A. P. et al. Dose-time-response relationship in peanut allergy using a human model of passive cutaneous anaphylaxis. J. Allergy Clin. Immunol. 139, 2015–2016.e2014 (2017).\n\nGruber, C. N. et al. Complex autoinflammatory syndrome unveils fundamental principles of JAK1 kinase transcriptional and biochemical function. Immunity 53, 672–684 e611 (2020).\n\nEgg, D. et al. Therapeutic options for CTLA-4 insufficiency. J. Allergy Clin. Immunol. 149, 736–746 (2022).\n\nOzen, A. et al. Broadly effective metabolic and immune recovery with C5 inhibition in CHAPLE disease. Nat. Immunol. 22, 128–139 (2021).\n\nCharbit-Henrion, F. et al. Genetic diagnosis guides treatment of autoimmune enteropathy. Clin. Gastroenterol. Hepatol. 21, 1368–1371.e1362 (2023).\n\nBarzaghi, F. et al. Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: an international multicenter retrospective study. J. Allergy Clin. Immunol. 141, 1036–1049.e1035 (2018).\n\nGoodwin, M. et al. CRISPR-based gene editing enables FOXP3 gene repair in IPEX patient cells. Sci. Adv. 6, eaaz0571 (2020).\n\nGustafsson, J. K. & Johansson, M. E. V. The role of goblet cells and mucus in intestinal homeostasis. Nat. Rev. Gastroenterol. Hepatol. 19, 785–803 (2022).\n\nMcDole, J. R. et al. Goblet cells deliver luminal antigen to CD103+ dendritic cells in the small intestine. Nature 483, 345–349 (2012).\n\nvan der Post, S. et al. Structural weakening of the colonic mucus barrier is an early event in ulcerative colitis pathogenesis. Gut 68, 2142 (2019).\n\nHe, G. W. et al. Optimized human intestinal organoid model reveals interleukin-22-dependency of paneth cell formation. Cell Stem Cell 29, 1333–1345.e1336 (2022).\n\nElmentaite, R. et al. Cells of the human intestinal tract mapped across space and time. Nature 597, 250–255 (2021).\n\nSpadoni, I. et al. A gut-vascular barrier controls the systemic dissemination of bacteria. Science 350, 830–834 (2015).\n\nMagri, G. et al. Human secretory IgM emerges from plasma cells clonally related to gut memory B cells and targets highly diverse commensals. Immunity 47, 118–134.e118 (2017).\n\nMayassi, T. et al. Chronic inflammation permanently reshapes tissue-resident immunity in celiac disease. Cell 176, 967–981.e919 (2019).\n\nMagnoumba, M. et al. Unbiased profiling reveals compartmentalization of unconventional T-cells within the intestinal mucosa irrespective of HIV infection. Front. Immunol. 11, 579743 (2020).\n\nZheng, Y. et al. Role of MAIT cells in gastrointestinal tract bacterial infections in humans: more than a gut feeling. Mucosal Immunol. 16, 740–752 (2023).\n\nKramer, B. et al. Compartment-specific distribution of human intestinal innate lymphoid cells is altered in HIV patients under effective therapy. PLoS Pathog. 13, e1006373 (2017).\n\nFawkner-Corbett, D. et al. Spatiotemporal analysis of human intestinal development at single-cell resolution. Cell 184, 810–826 e823 (2021).\n\nGogoleva, V. S. et al. LTalpha, TNF, and ILC3 in Peyer’s patch organogenesis. Cells 11, 1970 (2022).\n\nShayan, K., Saunders, F., Roberts, E. & Cutz, E. Adenovirus enterocolitis in pediatric patients following bone marrow transplantation: report of 2 cases and review of the literature. Arch. Pathol. Lab. Med. 127, 1615–1618 (2003).\n\nDesnues, B., Ihrig, M., Raoult, D. & Mege, J. L. Whipple’s disease: a macrophage disease. Clin. Vaccin. Immunol. 13, 170–178 (2006).\n\nGilmartin, A. A. & Petri, W. A.Jr Exploring the role of environmental enteropathy in malnutrition, infant development and oral vaccine response. Philos. Trans. R. Soc. Lond. B Biol. Sci. 370, 20140143 (2015).\n\nHossain, M. S. et al. Environmental enteric dysfunction and small intestinal histomorphology of stunted children in Bangladesh. PLoS Negl. Trop. Dis. 17, e0010472 (2023).\n\nAbuquteish, D. & Putra, J. Upper gastrointestinal tract involvement of pediatric inflammatory bowel disease: a pathological review. World J. Gastroenterol. 25, 1928–1935 (2019).\n\nKoutri, E. & Papadopoulou, A. Eosinophilic gastrointestinal diseases in childhood. Ann. Nutr. Metab. 73, 18–28 (2018).\n\nHamdulay, S. S. et al. Wireless capsule endoscopy in the investigation of intestinal Behcet’s syndrome. Rheumatology 47, 1231–1234 (2008).\n\nAlvarez-Lesmes, J. et al. Gastrointestinal tract lymphomas. Arch. Pathol. Lab. Med. 145, 1585–1596 (2021).\n\nPatey-Mariaud de Serre, N. et al. Digestive histopathological presentation of IPEX syndrome. Mod. Pathol. 22, 95–102 (2009).\n\nSerwas, N. K. et al. Atypical manifestation of LRBA deficiency with predominant IBD-like phenotype. Inflamm. Bowel Dis. 21, 40–47 (2015).\n\nCharbit-Henrion, F. et al. Genetic diagnosis guides treatment of autoimmune enteropathy. Clin. Gastroenterol. Hepatol. 21, 1368–1371.e2 (2022).\n\nBoth, T. et al. Inflammatory bowel disease in primary immunodeficiency disorders is a heterogeneous clinical entity requiring an individualized treatment strategy: a systematic review. Autoimmun. Rev. 20, 102872 (2021).\n\nLybil, M. A. & Genie, B. P063. Loeys-Dietz syndrome presenting with inflammatory bowel disease symptoms. Am. J. Gastroenterol. 114, S17 (2019).\n\nFrischmeyer-Guerrerio, P. A. et al. TGFbeta receptor mutations impose a strong predisposition for human allergic disease. Sci. Transl. Med. 5, 195ra194 (2013).\n\nKurteva, E., Lindley, K. J., Hill, S. M. & Koglmeier, J. Mucosal abnormalities in children with congenital chloride diarrhea-an underestimated phenotypic feature? Front. Pediatr. 8, 365 (2020).\n\nCai, C., Chen, Y., Chen, X. & Ji, F. Tufting enteropathy: a review of clinical and histological presentation, etiology, management, and outcome. Gastroenterol. Res. Pract. 2020, 5608069 (2020).\n\nTalbot, J. et al. Management of enteritis associated with tricohepatoenteric syndrome due to SKIV2L mutation using the combination of JAK1/2 inhibition and azathioprine. JPGN Rep. 3, e264 (2022).\n\nPatel, R. & Hyer, W. Practical management of polyposis syndromes. Frontline Gastroenterol. 10, 379–387 (2019).\n\nPena, A. S. What is the best histopathological classification for celiac disease? Does it matter? Gastroenterol. Hepatol. Bed Bench 8, 239–243 (2015).\n\nOberhuber, G. Histopathology of celiac disease. Biomed. Pharmacother. 54, 368–372 (2000).\n\nCorazza, G. R. & Villanacci, V. Coeliac disease. J. Clin. Pathol. 58, 573–574 (2005)."
    }
}